Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.41), $0.04 better than the analyst estimate of ($1.45). Revenue for the quarter came in at $28.91 million versus the consensus estimate of $26.26 million.

FINANCIAL GUIDANCE

As a result of the portfolio prioritization and corporate restructuring, REGENXBIO anticipates total savings of at least $100 million over the next two years. These anticipated cost savings along with $365 million in cash, cash equivalents and marketable securities as of September 30, 2023 are now expected to fund operations into the second half of 2025. This cash runway guidance is based on the Company\'s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under our ABBV-RGX-314 collaboration.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.